Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Tarlox (tarloxotinib bromide)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Molecular Templates, Pathos, Proacta, Signpath Pharma

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

NRG1 fusion	Solid Tumor	NRG1 fusion	Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
EGFR exon 20 mutation	Solid Tumor	EGFR exon 20 mutation	Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
HER-2 A775_G776insYVMA	Lung Adenocarcinoma	HER-2 A775_G776insYVMA	Lung Adenocarcinoma	tarloxotinib bromide Sensitive: C4 – Case Studies tarloxotinib bromide Sensitive : C4	tarloxotinib bromide Sensitive: C4 – Case Studies tarloxotinib bromide Sensitive : C4
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	tarloxotinib bromide Sensitive: D – Preclinical tarloxotinib bromide Sensitive : D	tarloxotinib bromide Sensitive: D – Preclinical tarloxotinib bromide Sensitive : D